Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About VIVOS INC
Vivos, Inc. is a radiation oncology medical device company. The company is headquartered in Richland, Washington. The company went IPO on 2001-08-08. The firm is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. The company is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Company’s IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The firm is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.
Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES BIOLASE, INC Bluejay Diagnostics, Inc. EKSO BIONICS HOLDINGS, INC. ENDRA Life Sciences Inc. GUIDED THERAPEUTICS INC PetVivo Holdings, Inc. Tenon Medical, Inc. VASO Corp
